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Acute myeloid leukemia cellsSialyl Lewis X (sLe X, CD15s) is a key antigen produced on tumor cell surfaces duringmultidrug resistance (MDR)
development. The present study investigated the effect of α1, 3 fucosyltransferase VII (FucT VII) and α2, 3
sialyltransferase IV (ST3Gal IV) on sLe X oligosaccharides synthesis as well as their impact onMDR development
in acutemyeloid leukemia cells (AML). FUT7 and ST3GAL4were overexpressed in three AMLMDR cells and bone
marrow mononuclear cells (BMMC) of AML patients with MDR by real-time polymerase chain reaction (PCR).
A close association was found between the expression levels of FUT7 and ST3GAL4 and the amount of sLe X
oligosaccharides, as well as the phenotypic variation of MDR of HL60 and HL60/ADR cells both in vitro and
in vivo. Manipulation of these two genes' expression modulated the activity of phosphoinositide-3 kinase
(PI3K)/Akt signaling pathway, thereby regulating the proportionally mutative expression of P-glycoprotein (P-gp)
and multidrug resistance related protein 1 (MRP1), both of which are known to be involved in MDR. Blocking the
PI3K/Akt pathway by its speciﬁc inhibitor LY294002 or Akt short hairpin RNA (shRNA) resulted in the reduced
MDR of HL60/ADR cells. This study indicated that sLe X involved in the development of MDR of AML cells probably
through FUT7 and ST3GAL4 regulating the activity of PI3K/Akt signaling pathway and the expression of P-gp and
MRP1.
© 2014 Elsevier B.V. All rights reserved.
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E1. Introduction
Acute myeloid leukemia (AML), the most common type of leukemia
in adults, has the lowest survival rate among all leukemias [1]. It is
a clonal malignancy of the hematopoietic system characterized by
accumulation of immature cell populations in the bone marrow or
peripheral blood [2]. Multidrug resistance (MDR) is a major challenge
to the successful treatment of AML. Classic MDR is the consequence of
overexpression of transporter proteins belonging to the ATP binding
cassette (ABC) family e.g., P-gp andMRP1, which lead to lower intracel-
lular drug accumulation and thus reduce cellular toxicity of chemother-
apeutic agents [3]. Nowadays, many researchers are managing to
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his work.adequately evaluate the interaction of glycan alterations and resistance
to chemotherapy of neoplastic cells so as to understand their pathogen-
esis. However, there is still little information about the role of glycosyl-
transferases and relevant glycogenes in the development of AML MDR
except the modiﬁcation of glycan structures has been observed in
drug-resistance leukemia cells [4,5].
Glycosylation is one of themost important modiﬁcations of proteins
and lipids [6]. Alterations in cell surface glycosylation are acknowledged
as a hallmark of carcinogenesis which usually leads to the expression
of tumor-associated carbohydrate antigens (TACAs) on glycoproteins
or glycolipids that decorate cell surfaces [7]. Lewis antigens are
functionally important terminal glycan epitopes, which are usually
subdivided into two groups: types 1 and 2, depending on whether
the terminal galactose is bound to the preceding GlcNAc by β-1,
3-galactosyltransferases (Gal-T) or β-1, 4 Gal-T [8]. All type 1 structures
contain a α1, 4-Fuc residue on the GlcNAc catalyzed by α1, 4-Fuc Ts
such as Lea, sLea and Leb. It is the same for type 2 antigens including
LeX, sLeX and LeY, but the linkage isα1, 3 instead (catalyzed byproducts
of FUT3 through -7 and FUT9) [9].
Sialyltransferases (STs) catalyzed the transformation of sialic acid
residues from donor substrate CMP-sialic acid to the oligosaccharide
side chains of glycoconjugates. Different STs showing cell and tissue tro-
pism are unique in substrate speciﬁcities and in types of linkage formed
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ST3Gal, ST6Gal, ST6GalNAc and ST8Sia. ST3Gal family is of α2, 3-STs
including six members ST3Gal I to ST3Gal VI [11], among ST3Gal III, IV
and VI have been reported to contribute to sLe X formation [12,13].
Fucosyltransferases (FucT) transfer fucose derived from the GDP-
fucose donor into different glycoconjugate acceptors, such as glycopro-
teins, glycolipids and oligosaccharides in α1, 2-(FUT1 and FUT2), α1,
3/4-(FUT3, FUT4, FUT5, FUT6, FUT7, FUT9, FUT10, and FUT11), and α1,
6-linkage (FUT8) [14,15], among Fuc Ts, α1, 3-Fuc Ts are found to be
responsible for the biosynthesis of sLe X and Le X. Interestingly, expres-
sion of FucT III, V, VI and VII is conferred byα1, 3-Fuc T that synthesized
sLe X [16].
SLe X overexpression is a common feature of several carcinomas and
it is associated with poor prognosis [17–19]. CD15s produced by FucT
VII and ST3Gal IV mediate leukemia cell inﬁltration [20]. High level
expression of ST3Gal III leads to cellular resistance to Taxol and thus
reduces the efﬁcacy of Taxol therapy [21]. Richard Ratei demonstrated
that the expression of sLe X was correlated with the positivity of AML
progenitor markers CD117 in the majority of AML cases. However, the
mechanism underlying sLe X-induced MDR in AML remains unclear.
Phosphoinositide 3 kinase (PI3K)/Akt signaling activation is impli-
cated in the progression of a wide variety of neoplasias [22]. Ample
evidences indicated that aberrant activation of PI3K/Akt pathway
leads to the short-term survival and drug resistance of different
types of human neoplasm cells [23,24], for example activation of Akt
associating with poor prognosis and chemotherapeutic resistance in
pediatric B-precursor acute lymphoblastic leukemia [25]. In leukemic
cells, chemoresistance is shown to bemaintained by PI3K/Akt signaling
activation, and could be reversed by LY294002, a known PI3K/Akt
antagonist [26].
In the present studywe investigated the effect of ST3GAL 4 and FUT7
expression on the synthesis of sLe X in three pairs of parental and
chemoresistant AML cell lines and in BMMC isolated from thediagnosed
AML patients.We further determined the functional role of sLe X inAML
MDR, as well as the possible mechanisms via PI3K/Akt pathway.
2. Materials and methods
2.1. Parental AML cell culture
Three AML cell lines including an acutemyelogenous leukemia (M2)
cell line HL60, an acute promyelocytic leukemia (M3) cell line NB4, and
a leukemic monocytic lymphoma (M5) cell line U937 were obtained
from the KeyGEN Company (China). All cell lines were cultured in
RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with
10% heat inactivated fetal bovine serum (Gibco) and 1% penicillin–
streptomycin (Gibco) at 37 °C in a humidiﬁed atmosphere containing
5% CO2. Adriamycin (Sigma) was added to parental cell cultures in step-
wise increasing concentrations from 1 μg/mL to 5 μg/mL for 2 months to
develop an adriamycin-resistant (ADR) subline, namely HL60/ADR, NB4/
ADR and U937/ADR, correspondingly. To maintain the MDR phenotype,
the complete medium of the resistant cell clones was supplemented
with 1.0mg/L adriamycin. Over 90% of ADR cellswere susceptible to sub-
sequent treatments if they were maintained in complete medium with-
out adriamycin for one week.
2.2. Samples from leukemia patients
101 previously untreated AML patients and 7 healthy donors were
included in this study. The diagnosis of AML was based on cytomor-
phology, cytochemistry, multiparameter ﬂow cytometry, immunology,
molecular genetics and cytogenetics, and the leukemic subtypes of
AML were determined according to the French–American–British clas-
siﬁcation as follows: 46, 37 and 18 cases ofM2,M3 andM5, respectively.
Therewere 71male and 30 femalewith age ranging from12 to 78 years
(median, 42 years). P-gp (+) was observed in 94 of 101 AML patients
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who were obtained from May 2010 to July 2012 at the First Afﬁliated
Hospital of Dalian Medical University (Dalian, China) provided written
informed consent. Both the study and the contents of the written con-
sent were approved by and the institutional ethics committees.
2.3. Separation of leukemic blast cells
BMMCwere separated by Ficoll-Hypaque density gradient centrifu-
gation from bone marrow or peripheral blood taken at the initial diag-
nosis and were further cultured in plastic dishes to remove adherent
cells at 37 °C for 24 h. Fresh separated non-adherent cells were main-
tained in modiﬁed Dulbecco's medium containing 10% fetal bovine
serum, 10 mM β-mercaptoethanol, 2 mM L-glutamine, 50 ng/mL
human stem cell factor, 10 ng/mL human interleukin-3, and 10 ng/mL
human interleukin-6.
2.4. Real time PCR analysis
ST3GAL3, ST3GAL4, ST3GAL6 and FUT7 mRNA levels of all the cells
were determined by real time PCR. Total RNA was isolated with Trizol
reagents (Gibco BRL, Rockville, MD, USA) and cDNA was synthesized
using QuantiTect Reverse Transcription Kit (QIAGEN, Valencia, CA)
according to the manufacturer's protocol. Real time PCR was carried out
on a Roche LightCycler480 real time PCR system (Applied Biosystems,
Foster City, CA) using QuantiTect SYBR Green PCR Kit (QIAGEN, Valencia,
CA). The sequences of the upstream and downstream primers were as
follows: 5′-TATGCTTCAGCCTTGATG-3′ and 5′-TTGGTGACTGACAAGA
TGG-3′ for ST3GAL3; 5′-ATGTTGGCTCTGGTCCTG-3′ and 5′-AGGAAGAT
GGG CTGATCC-3′ for ST3GAL4; 5′-ATGTCTATTGGGTGGCAC-3′ and 5′-
CGCACACA GAAAAGGGTG-3′ for ST3GAL6; 5′-CAACAGAGAAAGCAGG
CA-3′ and 5′-AAGAAACACACAGCCACC-3′ for FUT3; 5′-ATGGCAGTGGAA
CCTGTC-3′ and 5′-GCACCATCTCTGAGCAGC-3′ for FUT5; 5′-CATTTCTG
CTGCCTCAGG-3′ and 5′-GGGCAAGTCAGGCAACTC-3′ for FUT6; 5′-CCAC
GATCACCATCCTTG -3′ and 5′-AGGCTTCGGTTGGCACTC-3′ for FUT7; and
5′-CTCCTCCACCTTTGACG CTG-3′ and 5′-TCCTCTTGTGCTCTTGCTGG-3′
for GAPDH. The expression level of target genes was determined rela-
tively to GAPDH and calculated as 2−(CtTarget gene−CtGAPDH) .
2.5. Western blot analysis
Total cell protein was electrophoresed in 10% SDS-PAGE gel and
blotted onto a polyvinylidene diﬂuoridemembrane. After being blocked
with 5% powdered skim milk for 2 h in phosphate-buffered saline con-
taining 0.1% Tween 20 (PBST), the membranes were incubated with
rabbit anti-human ST3Gal III (Abcam, Cambridge, UK, 1:1000 dilution),
ST3Gal IV (Abcam, Cambridge, UK, 1:1000 dilution), ST3Gal VI (Abcam,
Cambridge, UK, 1:1000 dilution), FUT VII (Abgent, Cambridge, UK,
1:1000 dilution), KM93 (recognizing the sLe X, Merck, Temecula,
CA, 1:1000 dilution), Le X (Abcam, Cambridge, UK), Le Y (Abcam,
Cambridge, UK), PI3K p110α (Abgent, Cambridge, UK, 1:1000 dilution),
p-Akt 308 (Abgent, Cambridge, UK, 1:1000 dilution), p-Akt 473
(Abgent, Cambridge, UK, 1:1000 dilution) and Akt (Abgent, Cambridge,
UK, 1:1000 dilution) respectively at 4 °C overnight, and then incubated
with secondary antibody anti-rabbit-HRP or anti-mouse-HRP (1:2000
diluted, Santa Cruz Biotech, Santa Cruz, CA). GAPDH antibody (1:200
diluted, Santa Cruz Biotech, Santa Cruz, CA) was used as a control.
All bands were detected using ECL western blotting kit (Amersham
Biosciences, UK), according to the manufacturer's instruction.
2.6. Deregulation of ST3GAL4 or FUT7 by RNAi
HL60 or HL60/ADR cells were incubated in appropriate antibiotic-
freemediumwith 10% fetal bovine serum (Gibco), andwere transferred
to a 6well tissue culture incubating in a CO2 incubator to obtain 60–80%
conﬂuens at 37 °C. The cell cultures were transfected with ST3GAL4,
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trol. ST3GAL4 shRNA or FUT7 shRNA was mixed with Lipofectamine™
2000 (Invitrogen). Transfected cells were cultured and incubated at
37 °C for 6 h, followed by incubation with complete medium for addi-
tional 24 h. Then cells were harvested for further study. The cell trans-
fection efﬁciency was 85% by ﬂuorescent microscopy and the cell
viability was 90% by trypan blue dye exclusion assay.
2.7. Over-expression of ST3GAL4 or FUT7
The human ST3GAL4 and FUT7 coding sequences obtained from
TaKaRa company (Dalian, China) were inserted into the pEGFP-N2 vec-
tor (Invitrogen, Carlsbad, CA) at the sites of EcoRI and XhoI. Cells were
transfected with 5 μg of target gene expression vector or empty vector
(EV) in 100-mm dishes using PolyFect Transfection Reagent (QIAGEN,
Valencia, CA) according to the manufacturer's instruction. After
4 weeks of screening, the cell lines stably expressing ST3GAL4 (HL60/
ST3GAL4) and FUT7 (HL60/FUT7), and cells with empty vector (HL60/
mock) were established. Then cells were collected for gene expression
assay and further explorations. The cell transfection efﬁciency was
79% and the survival rate was 90%.
2.8. In vitro drug cytotoxic assay
The CellTiter 96® AQueous One Solution Cell Proliferation Assay
(MTS) kit (Promega, Madison, WI) was used to determine the chemo-
sensitivity of cell groups with genetic manipulation and pharmacologic
inhibition of the PI3K/Akt pathway. The tumor cells (1 × 104) were
seeded in 96-well plate and incubated with paclitaxel, vincristine,
and adriamycin (Sigma, St. Louis, MO) respectively for 48 h. Then the
cells were stained with 10 μL MTS at 37 °C for 3 h. The absorbance
was measured at 490 nm by microplate reader (Model 680; Bio-Rad,
Hercules, CA). The drug resistance was estimated by comparing the
IC50 values (drug concentration that inhibits cell growth by 50%) from
growth inhibition curves.
2.9. In vivo chemosensitivity assay
5-week-old nude mice were obtained from the Animal Facility of
Dalian Medical University and were fed with sterilized food and
water. Approximately, 1 × 107 cells of HL60, HL60/mock, HL60/
ST3GAL4, HL60/FUT7, HL60/ADR, HL60/ADR-control shRNA, HL60/
ADR-ST3GAL4 shRNA, or HL60/ADR-FUT7 shRNA were injected subcu-
taneously into the right ﬂank of each nude mouse. When mice bearing
palpable tumors (about 1 week after tumor cell inoculation), they
were randomly divided into control and treatment groups (n = 6
animals per group). The treatment groups received 7 mg/kg adriamycin
i.p. three times a week for 3 weeks, and the control groups received
physiological saline alone. The mice were sacriﬁced and their tumors
were isolated, weighed, and photographed. The tumor volume was
calculated by the following formula: Tumor volume = 1/2(length ×
width2).
2.10. Immunohistochemical (IHC) staining analysis
Visible tumors were removed from the mice and immunohisto-
chemistry was performed on parafﬁn embedded sections. The slides
were dried, deparafﬁnized, and rehydrated. After deparafﬁnization
and blocking of endogenous peroxidase, the slides were labeled with
antibodies (Abcam, Cambridge, UK) at a dilution of 1:200 at 4 °C over-
night. The secondary streptavidin-HRP-conjugated antibody staining
(Santa Cruz Biotech, Santa Cruz, CA) was performed at room tempera-
ture for 60 min. Finally, the sections were counterstained with hema-
toxylin and cover-slipped. The Image-Pro Plus4.5 Software (Media
Cybernetics, USA) was used to analyze the expression of proteins.
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LY294002 (Sigma) or Akt shRNAwas applied to suppress the activity
of the PI3K/Akt signaling in HL60/ADR cells. Brieﬂy, the tumor cells
(1 × 104 cells per well) were incubated in DMSO supplemented
with the PI3K inhibitor LY294002 (10 μM), Akt control shRNA and
Akt shRNA, and collected after 24 h. Variation in chemosensitivity
and gene expression were measured by MTS assay and western blot
analysis, respectively. Each experiment was run in triplicate to deter-
mine means and SDs.
2.12. Flow cytometry analysis
The tumor cells were washed with 1× phosphate buffered saline
(PBS) buffer containing 20 g/L bovine serum, and then were preincubat-
ed with 5% powdered skimmilk for 30min to block nonspeciﬁc binding.
For surface staining of P-gp, MRP and sLe X, aliquots of the cells (1 × 106)
were incubatedwith ﬂuorescein isothiocyanate (FITC)-anti human P-gp,
MRP1 (Abcam, Cambridge, UK), FITC-KM93 (Merck, Temecula, CA), or an
isotype control antibody (Santa Cruz Biotech, Santa Cruz, CA) at the rec-
ommendeddilutions at 4 °C for 40min. For detection ofα-2, 3 sialylation
and α-1, 3 fucosylation, the cell lysates were incubated with FITC-MAL
or AAL lectin (Sigma, St. Louis, MO, USA). After repeated centrifugation
at 1000 r/min, labeled cells were resuspended in 0.2 mL PBS and were
analyzed with FACSCalibur (BD Biosciences, San Jose, CA, USA). Fluores-
cence intensity was measured by Cell Quest software.
2.13. Statistical analysis
The data were expressed as mean ± standard deviation (SD) from
the triple tests of each group. SPSS17.0 software was used for statistical
analysis and Student's t-test was selected to determine the signiﬁcance
of differences among the examined groups. P b 0.05 was considered to
be statistically signiﬁcant.
3. Results
3.1. ST3GAL4 and FUT7 were responsible for the synthesis of sLe X in three
pairs of AML cell lines
To ﬁnd out the link between expression of glycosyltransferases and
expression of sLe X, the expression of sLe X in three pairs of AML cell
lines was ﬁrst evaluated by western blotting. A remarkable increase of
sLe X was observed in three MDR cells compared to that in the parental
cells (Fig. 1C).
The mRNA expression levels of ST3GAL3, ST3GAL4, ST3GAL6, FUT3,
FUT5, FUT6 and FUT7 were determined by real-time PCR analysis, and
α2, 3-STs and FucT VII expression levels were determined by western
blot analysis for the same AML cell lines. The three MDR cell lines with
higher expression of sLe X, also showed a tendency of an increasing
expression of ST3GAL4 (3.74 folds) and FUT7 (3.01 folds). Statistical sig-
niﬁcant differences were not found in the expression levels of ST3GAL3,
FUT3, FUT5 and FUT6 mRNA (Supplementary Fig. S1A), while ST3GAL6
was undetectable in both in drug-sensitive parental cells and MDR
cells (Fig. 1A, B). Our results indicated a positive association between
sLe X synthesis and expression of ST3GAL4 and FUT7 in AML cell lines.
3.2. Suppression of ST3GAL4 or FUT7 gene reduces the sLe X expression and
chemoresistance of HL60/ADR cells in vitro and in vivo
Due to the signiﬁcant increase of ST3GAL4or FUT7mRNAexpression
in HL60/ADR cells we silenced ST3GAL4 or FUT7 with shRNA in order
to elucidate their direct effects on the chemosensitivity of HL60/ADR
cells. As shown in Fig. 2A, B, the expression level of ST3GAL4 or FUT7
was signiﬁcantly decreased in HL60/ADR-shRNA transfectants com-
pared to those in the controls. Furthermore, α-2, 3 sialylation or α-1,
CT
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Fig. 1. Differential expression of ST3GAL3, ST3GAL4, ST3GAL6 and FUT7 in three pairs of AML cell lines. (A) The mRNA levels of ST3GAL3, ST3GAL4, ST3GAL6 and FUT7 analyzed by real-
time PCR. ThreeMDR cells expressed higher levels of ST3GAL4 and FUT7mRNA than their parental cell types (*P b 0.05). No signiﬁcant change of ST3GAL3was observed. ST3GAL6was not
detectable in MDR cells and their parental cells. (B) Western blotting analysis of ST3Gal III, ST3Gal IV, ST3Gal VI and FucT VII at protein levels. GAPDH served as a control. (C) By western
blot, sLe X was found to be highly expressed in three MDR cells compared to those of parental cells (*P b 0.05). Data are the means ± SD of triplicate determinants.
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shRNA-1 or HL60/ADR-FUT7 shRNA-1 cells by detecting FITC-
conjugated MAL or AAL on the cell surface (Fig. 2C, D). Following the
decreased expression of ST3GAL4 or FUT7, the expression of sLe X was
signiﬁcantly decreased in HL60/ADR-ST3GAL4 shRNA1 and HL60/
ADR-FUT7 shRNA1 cells (Fig. 3A, B). On the contrary, the expression of
Lewis X or Lewis Y, another glycan structure of the type 2 chains, was
signiﬁcantly increased in HL60/ADR cells treated with ST3GAL4 and
FUT7 shRNA (Supplementary Fig. S1B).
After ST3GAL4 or FUT7 shRNA transfection, the inhibition activity
to the growth of HL60/ADR was evaluated by MTS assay of adriamycin
and vincristine. The IC50 values were signiﬁcantly decreased in HL60/
ADR-ST3GAL4 shRNA1 cell group compared to the control, suggesting
that cell proliferation was inhibited by therapeutic drug when HL/60
cells were treated with ST3GAL4 shRNA. Similar results were obtained
inHL60/ADRFUT7 shRNA1 cell group that chemosensitivitywas remark-
ably restored when FUT7 gene was suppressed (Fig. 3C).
Nude mice bearing HL60/ADR, HL60-control shRNA, HL60/ADR-
ST3GAL4 shRNA-1 and HL60/ADR-FUT7 shRNA-1 xenografts were
used to determine the treatment efﬁcacy of adriamycin by measuring
tumor volumes. In HL60/ADR and HL60/ADR-control shRNA group,
there was no signiﬁcant change in tumor volumes regardless of drug
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T treatment. In HL60/ADR-ST3GAL4 shRNA1 group, the tumor volumeswere found reducing signiﬁcantly in the mouse group after drug treat-ment (Fig. 3D). The same tendency was also seen in HL60//ADR-FUT7shRNA1 group. IHC staining analysis of the tumor sections revealedthat the expressions of ST3Gal IV, FucT VII and sLe X were decreased
in the mouse group treated with ST3GAL4 shRNA1 or FUT7 shRNA1
compared to that in the untreated group (Fig. 3E–G).3.3. Overexpression of ST3GAL4 or FUT7 gene enhances the sLe X expression
and the chemoresistance of HL60 cells both in vitro and in vivo
To further identify the role of ST3GAL4 and FUT7 in the synthesis
of sLe X structures, we transfected HL60 cells with ST3GAL4 or FUT7
expression vector to determine the effect of over-expression of these
genes on chemoresistance of HL60 cells. Notably the levels of mRNA
and protein of ST3GAL4 and FUT7 were detected increasing in
ST3GAL4 and FUT7 transfectants (Fig. 4A, B). Fluorescence intensity of
the MAL or AAL revealed more α-2, 3 sialylation or α-1, 3 fucosylation
in HL60/ST3GAL4 or HL60/FUT7 cells were more than that in control
cells, since higher ﬂuorescence intensity of lectins was observed that
reﬂected higher expression of glycogene (Fig. 4C, D).
Fig. 2. Suppression of ST3GAL4 or FUT7 gene by RNAi. After shRNA transfection, distinct reduction of ST3GAL4 (A) or FUT7 (B) was observed at mRNA and protein levels. (C, D) Flow
cytometry analysis showed α-2, 3 sialylation or α-1, 3 fucosylation level detected by FITC-conjugated MAL or AAL on the cell surface, was also decreased in HL60/ADR-ST3GAL4 or
FUT7 shRNA1 cells. RA
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ﬂow cytometry. Higher level of sLe X was observed in HL60/ST3GAL4
and HL60/FUT7 cells when compared to the control (Fig. 5A, B).
To investigate the possible effects of sLe X expression on the
chemoresistance of HL60 cells, MTS assay was performed. The results
showed that the IC50 values of two drugs were signiﬁcantly higher in
HL60/ST3GAL4 and HL60/FUT7 cells than in HL60 cells, suggesting a
positive association between the sLe X expression and chemoresistance
of leukemia cells (Fig. 5C).
The nudemice inoculated with tumor cells HL60, HL60/mock, HL60/
ST3GAL4 and HL60/FUT7 were used to measure and compare tumor
volumes with or without adriamycin treatment. In the group of mice
bearing HL60 tumors, tumor volume was reduced after adriamycin
treatment than those without. In the group of mice bearing HL60/
ST3GAL4 or FUT7 tumors, tumor volumes increased obviously even
after adriamycin treatment (Fig. 5D). High expression of ST3Gal IV,
FucT VII and sLe X was illustrated in the tumor cells of HL60/ST3GAL4
or HL60/FUT7 by IHC staining, as shown in Fig. 5E–G. Therefore up-
regulation of ST3GAL4 or FUT7 gene in HL60 cells led to increasing resis-
tance to adriamycin chemotherapy.
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T 3.4. Effect of sLe X-activated PI3K/Akt signaling pathway on the expressionof P-gp and MRP1
In order to investigate whether sLe X activated the PI3K/Akt
pathway and whether this pathway was involved in sLe X-mediated
cell MDR, western blotting was applied to measure the levels of the
main molecules of PI3K/Akt signaling pathway, P110α (the catalytic
subunit of PI3K), phosphorylation Akt at Ser473 and Thr308. Fig. 6A
showed that the levels of the three main molecules were signiﬁcantly
decreased in low sLe X expression cells (HL60/ADR-ST3GAL4 shRNA1
cells and HL60/ADR-FUT7 shRNA1 cells). On the contrary, the expres-
sion of all of the above-mentioned molecules was obviously increased
in sLe X over expression cells (HL60 cells treated with ST3GAL4
and FUT7 expression vector) (Fig. 6B). However, there was no change
in the total amount of Akt protein.
Further on, we investigated whether sLe X inﬂuence the expression
of P-gp and MRP1. Interestingly, ﬂow-cytometric analysis illustrated
that elevated expression levels of P-gp and MRP1 were detected in
high sLe X expressing cells compared to those in the control groups
(Fig. 6D). In contrast, HL60/ADR cells with sLe X suppression expressed
RE
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Fig. 4.Overexpression of ST3GAL4 or FUT7 gene. After full-length sequence transfection, expression levels of ST3GAL4 (A) and FUT7 (B) were increased notably in HL60 cells by real time
PCR andwestern blot. (C, D) Flow cytometry analysis showedα-2, 3 sialylation orα-1, 3 fucosylation level detected by FITC-conjugatedMAL or AAL on the cell surface, was also increased
in HL60/ST3GAL4 or HL60/FUT7 cells.
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pathogenetic mechanism of MDR development of AML cells.
3.5. PI3K/Akt inhibition modulates the chemosensitivity of HL60/ADR cells
both in vitro and in vivo
The effect of PI3K/Akt signaling activity on chemoresistance of HL60/
ADR cells was explored by pharmacologic inhibition of the PI3K/Akt
pathway. By western blotting, the expression levels of the main signal
molecules of PI3K/Akt pathway apparently decreased in HL60/ADR
cells treated with LY294002 or Akt shRNA (Fig. 7A). As shown in
Fig. 7B, the inhibition of PI3K/Akt pathway resulted in the HL60/ADR
cells susceptible to chemotherapy. Accordingly in vivo chemosensitivity
analysis revealed that reduced tumor volumes were detected in mice
group bearing HL60/ADR tumors with impaired PI3K/Akt signaling
(Fig. 7C). Altered expression levels of the main signal molecules of
ET
RFig. 3. Silence of ST3GAL4 or FUT7 gene enhances the chemosensitivity of HL60/ADR cells bot
FUT7 shRNA1 cells by western blotting analysis (A) and ﬂow cytometry analysis (B). (C) Cell
(mean± SD) of three independent experiments. IC50 represents the drug concentration produc
of mean tumor volume in mice group with HL60/ADR-ST3GAL4 or FUT7 shRNA1 tumors was o
Within HL60/ADR-ST3GAL4 or FUT7 shRNA1 group, an increase of tumor growthwas found in g
ST3Gal IV, FucT VII or sLe Xwas also shown by IHC staining in xenograft tumors derived fromHL
SD of 3 independent assays (*P b 0.05).PI3K/Akt pathway were also validated in mouse group bearing HL60/
ADR tumors treated with LY294002 or Akt shRNA treatment were also
validated by IHC staining, as shown in Fig. 7D.
As well, we revealed the same tendency of ZSTK474, a novel PI3K/
Akt pathway inhibitor, in HL60/ADR cells (Supplementary Fig. S2).
Moreover, the inhibitor of PI3K/Akt or silencing Akt reduced the
expression of P-gp and MRP1 (Fig. 7E). The results implicated a role of
PI3K/Akt signaling in regulating P-gp and MRP1 expression and modu-
lating the chemoresistance of HL60/ADR cells.
3.6. ST3GAL4 and FUT7were responsible for the synthesis of sLe X in BMMC
of AML patients
Expression of MDR-related marker, ST3GAL3, ST3GAL4, ST3GAL6
and FUT7 presenting in BMMC of AML patients is summarized in
Table 1. The frequency of P-gp positivity was 93.06% (94 of 101) in theh in vitro and in vivo. Distinct reduction of sLe X was observed in HL60/ADR-ST3GAL4 or
chemosensitivity was assessed by cytotoxicity assays. The reported values were the IC50
ing 50% decrease of cell growth. *P b 0.05 vs HL60/ADR-control shRNA cells. (D) A decrease
bserved, as compared with that in HL60/ADR group and HL60/ADR-control shRNA group.
roupwithout ADR, comparedwith that with ADR (*P b 0.05). (E, F, G) Down-regulation of
60/ADR-ST3GAL4 shRNA1 orHL60/ADR-FUT7 shRNA1 cells (400×). The data aremeans±
Fig. 5. Overexpression of ST3GAL4 or FUT7 gene enhances the chemoresistance of HL60 cells both in vitro and in vivo. Western blotting analysis (A) and ﬂow cytometry analysis
(B) showed a signiﬁcantly increased expression of sLe X in HL60/ST3GAL4 or HL60/FUT7 cells. The chemoresistance of HL60 cells was increased with the ST3GAL4 or FUT7 expression
vector transfection in vitro (C) and in vivo (D). (E, F, G) Up-regulation of ST3Gal IV, FucT VII or sLe X was also shown by IHC staining in xenograft tumors derived from HL60/ST3GAL4
or HL60/FUT7 cells (400×). The data are means ± SD of 3 independent assays (*P b 0.05).
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Fig. 6. Effect of ST3GAL4 or FUT7-activated PI3K/Akt signaling pathway on the expression of P-gp andMRP1. (A) Expression of PI3K/Akt signalingmoleculeswas repressed at protein levels
with ST3GAL4 or FUT7 shRNA transfection in HL60/ADR cells. (B) The increased expression levels of PI3K/Akt signaling molecules were determined by western blot in HL60/ST3GAL4
or FUT7 cells. (C) Decreased expressions of P-gp and MRP1 were examined by ﬂow cytometry analysis in ST3GAL4 or FUT7-shRNA-treated HL60/ADR cells. (D) Flow cytometry analysis
revealed a higher expression of P-gp and MRP1 in HL60 cells with ST3GAL4 or FUT7 transfection. The data are means ± SD of 3 independent assays (*P b 0.05).AC
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and FUT7 were measured in the BMMC of AML without MDR and
AML/MDR by realtime PCR and ﬂow cytometry analysis of sLe X ﬂuores-
cence intensity. The groups ofM2/MDR,M3/MDR andM5/MDR showed
signiﬁcant higher levels of ST3GAL4 and FUT7 mRNA expression and
high ﬂuorescence intensity of sLe X than ones of the chemosensitive
group. ST3GAL3 showed no difference in expression levels between
the two groups, while ST3GAL6 was detected slightly.
4. Discussion
MDR is the major obstacle to the efﬁciency of chemotherapy in the
treatment of leukemia [27]. In this study, we investigated the associa-
tion between sLe X expression and clinicopathological characteristics
of AML as well as the possible mechanism of sLeX oligosaccharides on
MDR development in human AML cell lines.
Sialylated antigens are expressed on the surface of various human
cancer cells and are assumed to play a key role in the process of tumor
progression [28]. sLe X is the major terminal carbohydrate structure
that binds selectins and interferes in tumor cell rolling and metastasis
[29]. The present study unraveled the role of ST3Gal IV and FucT VII in
the biosynthesis and the regulation of the expression of sLe X in AML
cells. Our observations were in agreement with the previous studies
showing that expression of ST3Gal IV in Burkitt lymphoma cell line
and FucT VII in H7721 cells led to the production of sLe X [30,31].
RE
TOverexpression of sialylated Lewis antigens in AML cells indicated an
alteration of the glycosyltransferases expression and activity. The
present study showed here that all MDR cells were characterized by
high levels of sLe X, ST3GAL4 and FUT7, suggesting that the drug
resistant AML cell lines produced altered α2, 3-sialylation and
α1, 3-fucosylation. The alternation of the expression of sLe X,
ST3GAL4 and FUT7 can be regarded as indicators and functional
contributors for tumor MDR.
The question then arises whether and how the alteration of MDR in
AML cells is caused by the change of ST3Gal IV, FucT VII or their product
sLe X. Our former work demonstrated that the expression of ST3GAL4
involved in drug resistance development in chronic myeloid leukemia
(CML) cell lines K562 and K562/ADR [5]. The present investigation illus-
trated that the altered level of ST3GAL4 or FUT 7 led to drug-resistant
phenotype changes of HL60 and HL60/ADR cells. This conclusion was
evidenced by the following observations. (1) Expression level of sLe X
was remarkably decreased (Fig. 2E, F), and IC50 values of chemotherapy
drugs were signiﬁcantly decreased in HL60/ADR-ST3GAL4 or FUT 7
shRNA-1 cell group. Correspondingly reduced tumor volumes were
detected in mice group bearing HL60/ADR-ST3GAL4 or FUT 7 shRNA-1
tumors by in vivo chemosensitivity analysis. (2) Overexpression of
ST3GAL4 or FUT7 gene enhanced the sLe X expression, further the
chemoresistance of HL60 cells both in vitro and in vivo. Based on these
results we hypothesized that ST3Gal IV, FucT VII and their product sLe
X might function as pivotal modulators in MDR development of AML.
Fig. 7. PI3K/Akt inhibitionmodulates the chemosensitivity ofHL60/ADRcells both in vitro and in vivo. (A) TheHL60/ADR cellswere pretreated LY294002 or Akt shRNA. Expression of PI3K/
Akt signaling molecules was then examined by western blot analysis. (B) LY294002 or Akt shRNA treatment also alleviated chemoresistance of HL60/ADR cells, revealed by in vitro and
in vivo (C). (D) Down-regulation of PI3K/Akt signaling molecules was also shown by IHC staining in xenograft tumors derived from LY294002 or Akt shRNA treatment cells (400×).
(E) Flow cytometry analysis showed that suppression of PI3K/Akt signaling resulted in reduced level of P-gp and MRP1. The data are means ± SD of 3 independent assays. ⁎P b 0.05 vs
DMSO treatment cells; #P b 0.05 vs control shRNA treatment cells. RA
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over activated in AML cells, which controls the expression and function
of numerous proteins that are necessary for tumor cell MDR [32–35].
Activity of PI3K inhibitors (for example, wortmannin and LY294002)
TTable 1
Expressional proﬁles of ST3GAL3, ST3GAL4, ST3GAL6, FUT7 and sLe X in AML and AML/MDR p
Gene Relative mRNA expression (×103) P-value Relative mRNA expres
M2 M2/MDR M3 M
ST3GAL3 14.885 ± 0.762 15.031 ± 2.552 0.923 14.239 ± 0.547 1
ST3GAL4 9.488 ± 0.783 23.466 ± 7.011 0.002⁎ 9.235 ± 0.841 2
ST3GAL6 0.005 ± 0.001 0.004 ± 0.002 0.398 0.006 ± 0.001
FUT7 10.187 ± 0.819 18.552 ± 6.031 0.021⁎ 10.728 ± 0.744 1
Fluorescence intensity (%)
sLe X 47.818 ± 2.691 68.674 ± 16.879 0.040⁎ 45.561 ± 1.603 7
⁎ P b 0.05 vs M2 patients.
⁎⁎ P b 0.05 vs M3 patients.
⁎⁎⁎ P b 0.05 vs M5 patients.
REin combination with chemotherapy is currently studied in cancer cell
lines and animal models [36]. Expression of ST3GAL4 induces c-Met
which gives rise to sLe X expression. c-Met, a unique receptor tyrosine
kinase (RTK), can activate several crucial cellular growth pathways,atients.
sion (×103) P-value Relative mRNA expression (×103) P-value
3/MDR M5 M5/MDR
5.263 ± 2.358 0.548 14.627 ± 0.244 15.491 ± 2.013 0.563
1.702 ± 6.618 0.010⁎⁎ 9.301 ± 0.833 22.485 ± 6.927 0.018⁎⁎⁎
0.005 ± 0.002 0.491 0.006 ± 0.001 0.004 ± 0.003 0.373
9.583 ± 5.784 0.040⁎⁎ 9.793 ± 0.665 19.204 ± 5.835 0.041⁎⁎⁎
0.266 ± 14.825 0.026⁎⁎ 48.359 ± 1.411 72.627 ± 15.002 0.041⁎⁎⁎
1691H. Ma et al. / Biochimica et Biophysica Acta 1842 (2014) 1681–1692including the PI3K/Akt pathway [37,38]. Moreover, the upregulation
of cell surface sLe X and FucT VII ismediated by PI3K/Akt signaling path-
way [39]. The present study demonstrated that the resistant cell line
HL60/ADR presented higher PI3K/Akt activity than the sensitive one,
which was in accordance with the MDR phenotype. Altered expression
of ST3GAL4 or FUT7 markedly modulated the activity of PI3K/Akt
pathway in human AML cell lines. In addition, inhibition of the PI3K/
Akt pathwaywith Akt-speciﬁc inhibitor LY294002, or Akt gene silencing
by shRNA pretreatment reversed chemoresistance of HL60/ADR cells.
Our results together with the previous ﬁndings, explored a possible
mechanism of MDR in AML cells that drug resistance might develop
and vary via the PI3K/Akt pathway activated by sLe X overexpres-
sion. sLe X-modulated AML cell MDR was, at least in part, PI3K/Akt-
dependent.
To date, tremendous evidence indicates that tumor cellsmaintain the
MDR through the PI3K/Akt pathway enhancing drug efﬂux by ATP-
binding cassette (ABC) transporters [40]. PI3K inhibitor, LY294002,
therefore has therapeutic potential in the treatment of MRP1-mediated
drug resistance when combined with doxorubicin [41], since it is able
to block P-gp expression in mouse leukemic cell lines [42]. As two
main members of ABC transporters, P-gp and MRP1 are frequently
used as markers to screen MDR patients clinically. In addition, it has
been well demonstrated that sLe X could affect EGFR dimerization [43],
which activates distinct downstream signaling such as the PI3K/Akt
pathway, and constitutive activation of PI3K/Akt is associated with the
expression of ST3GAL4 and FUT7 [37–39]. Therefore, a close association
is indicated between the levels of sLe X, ST3GAL4 and FUT7 and the levels
of phosphorylated Akt, as well as P-gp, MRP1 expression in AML cells.
In this study, we showed that, the levels of P-gp and MRP1 had a
proportional relationship with the expression of ST3GAL4 and FUT7
and the activity of PI3K/Akt signaling in HL60 or HL60/ADR cell lines.
Since ST3GAL4 or FUT7 was observed as regulatory gene for the ex-
pression of sLe X, which regulated the activity of PI3K/Akt signaling, we
assume that ST3GAL4 or FUT7 regulates the expression of P-gp and
MRP1 via sLe X inducing PI3K/Akt pathway, consequently promoting
MDR of AML cells.
Although the clinical outcome of AML has been improved with
advancements in chemotherapy, MDR remained a critical challenge
for successful treatment. Our previous research showed that B4GALT1
and B4GALT5 (two members of β-1, 4-galactosyltransferase gene
family) were highly expressed in the BMMC of leukemia patients with
MDR, and these two geneswere determined to be involved in the devel-
opment of MDR by regulating the activity of Hh signaling and the ex-
pression of P-gp and MRP1 [44]. In the present study, more than 93%
of the AML patients were found resistant to the anticancer drugs.
ST3GAL4, FUT7 and sLe X were expressed at a high level in BMMC of a
signiﬁcant proportion of AML/MDR patients. Once again the ﬁndings
from the clinical samples conﬁrmed that altered levels of these genes
were probably associated with MDR phenotype in AML. On the basis
of the above results, it implies the utilization of ST3GAL4 or FUT7 as
biomarkers for clinical diagnosis and prognosis of MDR of AML and as
potential targets for therapeutic approaches in the future.
In conclusion, our data demonstrated that expression of ST3GAL4
and FUT7 could regulate sLe X oligosaccharide synthesis and sLe
X-mediated MDR of AML by activating the PI3K/Akt pathway and the
expression of P-gp and MRP1. Seeking for agents that simultaneously
inhibit ST3Gal IV or FucT VII might be a promising strategy for clinical
diagnosis, prognosis evaluation and treatment of MDR of AML.
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